The Utility of a Rapid Review Evaluation Process to a National HTA Agency

• Published in: PharmacoEconomics 2022-02, Vol.40 (2), p.203-214
• Main Authors: Varley, Áine, Tilson, Lesley, Fogarty, Emer, McCullagh, Laura, Barry, Michael
• Format: Article
• Language: English
• Subjects: Cancer; Care and treatment; Cost control; Drug Costs; Drugs; Economics, Pharmaceutical; Health Administration; Health Economics; Health technology assessment; Humans; Medical economics; Medicine; Medicine & Public Health; Organizations; Original; Original Research Article; Pharmaceutical industry; Pharmacoeconomics; Pharmacoeconomics and Health Outcomes; Public Health; Quality of Life Research; Reimbursement; Retrospective Studies; Technology Assessment, Biomedical - methods
• ISSN: 1170-7690; 1179-2027
• DOI: 10.1007/s40273-021-01093-8

Background and Objective In Ireland, similar to other jurisdictions, health technology assessment (HTA) is used to inform the health payer’s drug reimbursement decisions. These HTAs are conducted by the National Centre for Pharmacoeconomics (NCPE). In 2009, the NCPE introduced the Rapid Review process to identify drugs that do not require further assessment in the form of the previously established full HTA process. Methods A retrospective analysis of all Rapid Reviews submitted to the NCPE from 2010 to 2019, inclusive, was conducted. Rapid Review recommendation was recorded (i.e. full HTA required or not required). For those submitted from 2012 to 2019, additional data relating to the drug, economic and clinical evidence-related factors were collected. Multivariable logistic regression methods were used to model the relationship between these factors and the likelihood of requiring a full HTA. An exploratory analysis estimated the additional NCPE appraisal time that would have been required to evaluate all drugs, had the Rapid Review process not been established. Results Of the 446 Rapid Reviews submitted, approximately half (49.6%) were deemed to require a full HTA. Drugs for cancer indications, drugs designated first-in-class status, and high-cost drugs were positively and significantly associated with the likelihood of requiring a full HTA. No significant association was found for drugs for orphan indications when factors relating to cost and clinical evidence were included in the model. Without the Rapid Review process, an estimated additional 15,631 NCPE appraisal days would have been required to evaluate all drugs submitted over the 10-year period. Conclusions This is the first study to use data uniquely available to the NCPE to evaluate factors associated with the requirement for a full HTA following a Rapid Review. The process has reduced the NCPE appraisal time required to evaluate all submissions over the study period. The NCPE’s Rapid Review process allows for appropriate resource prioritisation within a national HTA agency.